229 related articles for article (PubMed ID: 38146999)
1. Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group.
Mueller S; Fangusaro J; Thomas AO; Jacques TS; Bandopadhayay P; de Blank P; Packer RJ; Fouladi M; van Meeteren AS; Jones D; Perry A; Nakano Y; Hargrave D; Riedl D; Robison NJ; Partanen M; Fisher MJ; Witt O
Neuro Oncol; 2024 Mar; 26(3):407-416. PubMed ID: 38146999
[TBL] [Abstract][Full Text] [Related]
2. Pediatric low-grade glioma: State-of-the-art and ongoing challenges.
Fangusaro J; Jones DT; Packer RJ; Gutmann DH; Milde T; Witt O; Mueller S; Fisher MJ; Hansford JR; Tabori U; Hargrave D; Bandopadhayay P
Neuro Oncol; 2024 Jan; 26(1):25-37. PubMed ID: 37944912
[TBL] [Abstract][Full Text] [Related]
3. Corrigendum to: Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group.
Neuro Oncol; 2024 May; 26(5):984. PubMed ID: 38395429
[No Abstract] [Full Text] [Related]
4. Corrigendum to: Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group.
Neuro Oncol; 2024 May; 26(5):983. PubMed ID: 38366877
[No Abstract] [Full Text] [Related]
5. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
Perreault S; Larouche V; Tabori U; Hawkin C; Lippé S; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; Sultan S; Cantin É; Routhier MÈ; Caru M; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Jabado N
BMC Cancer; 2019 Dec; 19(1):1250. PubMed ID: 31881853
[TBL] [Abstract][Full Text] [Related]
6. LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.
van Tilburg CM; Kilburn LB; Perreault S; Schmidt R; Azizi AA; Cruz-Martínez O; Zápotocký M; Scheinemann K; Meeteren AYNS; Sehested A; Opocher E; Driever PH; Avula S; Ziegler DS; Capper D; Koch A; Sahm F; Qiu J; Tsao LP; Blackman SC; Manley P; Milde T; Witt R; Jones DTW; Hargrave D; Witt O
BMC Cancer; 2024 Jan; 24(1):147. PubMed ID: 38291372
[TBL] [Abstract][Full Text] [Related]
7. Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma.
Manoharan N; Choi J; Chordas C; Zimmerman MA; Scully J; Clymer J; Filbin M; Ullrich NJ; Bandopadhayay P; Chi SN; Yeo KK
J Neurooncol; 2020 Sep; 149(2):253-262. PubMed ID: 32780261
[TBL] [Abstract][Full Text] [Related]
8. Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions-International Pediatric Low-Grade Glioma Coalition.
O'Hare P; Cooney T; de Blank P; Gutmann DH; Kieran M; Milde T; Fangusaro J; Fisher M; Avula S; Packer R; Fukuoka K; Mankad K; Mueller S; Waanders AJ; Opocher E; Bouffet E; Raabe E; Werle NE; Azizi AA; Robison NJ; Hernáiz Driever P; Russo M; Schouten N; van Tilburg CM; Sehested A; Grill J; Bandopadhayay P; Kilday JP; Witt O; Ashley DM; Ertl-Wagner BB; Tabori U; Hargrave DR
Neuro Oncol; 2024 May; ():. PubMed ID: 38743009
[TBL] [Abstract][Full Text] [Related]
9. Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma Clinical Trials: An FDA Educational Symposium.
Fangusaro J; Avery RA; Fisher MJ; Packer RJ; Walsh KS; Schouten-van Meeteren A; Karres D; Bradford D; Bhatnagar V; Singh H; Kluetz PG; Donoghue M; Duke ES
Clin Cancer Res; 2024 Jun; 30(11):2303-2308. PubMed ID: 38358393
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials referral resource. Multicenter phase I and II trials in adults with high-grade gliomas.
Kaplan RS; Smiley JK; Cheson BD
Oncology (Williston Park); 1999 Apr; 13(4):532-3, 537. PubMed ID: 10234703
[No Abstract] [Full Text] [Related]
11. Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.
Fangusaro J; Witt O; Hernáiz Driever P; Bag AK; de Blank P; Kadom N; Kilburn L; Lober RM; Robison NJ; Fisher MJ; Packer RJ; Young Poussaint T; Papusha L; Avula S; Brandes AA; Bouffet E; Bowers D; Artemov A; Chintagumpala M; Zurakowski D; van den Bent M; Bison B; Yeom KW; Taal W; Warren KE
Lancet Oncol; 2020 Jun; 21(6):e305-e316. PubMed ID: 32502457
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Pediatric Low-Grade Gliomas.
Sait SF; Giantini-Larsen AM; Tringale KR; Souweidane MM; Karajannis MA
Curr Neurol Neurosci Rep; 2023 Apr; 23(4):185-199. PubMed ID: 36881254
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy in pediatric low-grade glioma.
Kilday JP; Bartels UK; Bouffet E
Curr Neurol Neurosci Rep; 2014 Apr; 14(4):441. PubMed ID: 24604059
[TBL] [Abstract][Full Text] [Related]
14. Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations.
Miklja Z; Pasternak A; Stallard S; Nicolaides T; Kline-Nunnally C; Cole B; Beroukhim R; Bandopadhayay P; Chi S; Ramkissoon SH; Mullan B; Bruzek AK; Gauthier A; Garcia T; Atchison C; Marini B; Fouladi M; Parsons DW; Leary S; Mueller S; Ligon KL; Koschmann C
Neuro Oncol; 2019 Aug; 21(8):968-980. PubMed ID: 30805642
[TBL] [Abstract][Full Text] [Related]
15. WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial.
Varlet P; Le Teuff G; Le Deley MC; Giangaspero F; Haberler C; Jacques TS; Figarella-Branger D; Pietsch T; Andreiuolo F; Deroulers C; Jaspan T; Jones C; Grill J
Neuro Oncol; 2020 Jan; 22(1):116-127. PubMed ID: 31419298
[TBL] [Abstract][Full Text] [Related]
16. Molecular markers and targeted therapy in pediatric low-grade glioma.
de Blank P; Fouladi M; Huse JT
J Neurooncol; 2020 Oct; 150(1):5-15. PubMed ID: 32399739
[TBL] [Abstract][Full Text] [Related]
17. Metronomic Maintenance With Weekly Vinblastine After Induction With Bevacizumab-Irinotecan in Children With Low-grade Glioma Prevents Early Relapse.
Roux C; Revon-Rivière G; Gentet JC; Verschuur A; Scavarda D; Saultier P; Appay R; Padovani L; André N
J Pediatr Hematol Oncol; 2021 Jul; 43(5):e630-e634. PubMed ID: 33235152
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy for high-grade gliomas of childhood.
Pollack IF; Boyett JM; Finlay JL
Childs Nerv Syst; 1999 Oct; 15(10):529-44. PubMed ID: 10550584
[TBL] [Abstract][Full Text] [Related]
19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
20. Current and future directions for Phase II trials in high-grade glioma.
Alexander BM; Lee EQ; Reardon DA; Wen PY
Expert Rev Neurother; 2013 Apr; 13(4):369-87. PubMed ID: 23545053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
